S&P 500   4,366.82 (-1.72%)
DOW   34,399.08 (-1.35%)
QQQ   361.63 (-2.35%)
AAPL   142.42 (-2.03%)
MSFT   285.03 (-3.11%)
FB   342.03 (-3.27%)
GOOGL   2,730.43 (-3.23%)
TSLA   780.96 (-1.31%)
AMZN   3,314.47 (-2.68%)
NVDA   208.26 (-3.85%)
BABA   152.84 (+1.77%)
NIO   35.32 (-3.94%)
CGC   14.23 (-3.26%)
GE   106.14 (+0.75%)
MU   73.78 (-1.86%)
AMD   102.39 (-5.33%)
T   27.30 (-0.36%)
F   14.37 (+1.48%)
ACB   6.80 (+6.42%)
DIS   174.82 (-1.93%)
PFE   43.19 (-0.87%)
BA   219.50 (-2.08%)
AMC   37.58 (-4.38%)
S&P 500   4,366.82 (-1.72%)
DOW   34,399.08 (-1.35%)
QQQ   361.63 (-2.35%)
AAPL   142.42 (-2.03%)
MSFT   285.03 (-3.11%)
FB   342.03 (-3.27%)
GOOGL   2,730.43 (-3.23%)
TSLA   780.96 (-1.31%)
AMZN   3,314.47 (-2.68%)
NVDA   208.26 (-3.85%)
BABA   152.84 (+1.77%)
NIO   35.32 (-3.94%)
CGC   14.23 (-3.26%)
GE   106.14 (+0.75%)
MU   73.78 (-1.86%)
AMD   102.39 (-5.33%)
T   27.30 (-0.36%)
F   14.37 (+1.48%)
ACB   6.80 (+6.42%)
DIS   174.82 (-1.93%)
PFE   43.19 (-0.87%)
BA   219.50 (-2.08%)
AMC   37.58 (-4.38%)
S&P 500   4,366.82 (-1.72%)
DOW   34,399.08 (-1.35%)
QQQ   361.63 (-2.35%)
AAPL   142.42 (-2.03%)
MSFT   285.03 (-3.11%)
FB   342.03 (-3.27%)
GOOGL   2,730.43 (-3.23%)
TSLA   780.96 (-1.31%)
AMZN   3,314.47 (-2.68%)
NVDA   208.26 (-3.85%)
BABA   152.84 (+1.77%)
NIO   35.32 (-3.94%)
CGC   14.23 (-3.26%)
GE   106.14 (+0.75%)
MU   73.78 (-1.86%)
AMD   102.39 (-5.33%)
T   27.30 (-0.36%)
F   14.37 (+1.48%)
ACB   6.80 (+6.42%)
DIS   174.82 (-1.93%)
PFE   43.19 (-0.87%)
BA   219.50 (-2.08%)
AMC   37.58 (-4.38%)
S&P 500   4,366.82 (-1.72%)
DOW   34,399.08 (-1.35%)
QQQ   361.63 (-2.35%)
AAPL   142.42 (-2.03%)
MSFT   285.03 (-3.11%)
FB   342.03 (-3.27%)
GOOGL   2,730.43 (-3.23%)
TSLA   780.96 (-1.31%)
AMZN   3,314.47 (-2.68%)
NVDA   208.26 (-3.85%)
BABA   152.84 (+1.77%)
NIO   35.32 (-3.94%)
CGC   14.23 (-3.26%)
GE   106.14 (+0.75%)
MU   73.78 (-1.86%)
AMD   102.39 (-5.33%)
T   27.30 (-0.36%)
F   14.37 (+1.48%)
ACB   6.80 (+6.42%)
DIS   174.82 (-1.93%)
PFE   43.19 (-0.87%)
BA   219.50 (-2.08%)
AMC   37.58 (-4.38%)
NASDAQ:OCUL

Ocular Therapeutix Stock Forecast, Price & News

$10.49
-0.34 (-3.14 %)
(As of 09/28/2021 03:25 PM ET)
Add
Compare
Today's Range
$10.37
$10.69
50-Day Range
$9.70
$12.68
52-Week Range
$7.50
$24.30
Volume11,308 shs
Average Volume935,956 shs
Market Capitalization$803.36 million
P/E RatioN/A
Dividend YieldN/A
Beta2.14
30 days | 90 days | 365 days | Advanced Chart
Receive OCUL News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.


Ocular Therapeutix logo

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OCUL
Employees
181
Year Founded
N/A

Sales & Book Value

Annual Sales
$17.40 million
Book Value
$1.00 per share

Profitability

Net Income
$-155,640,000.00
Net Margins
-318.77%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$803.36 million
Next Earnings Date
11/4/2021 (Estimated)
Optionable
Optionable

MarketRank

Overall MarketRank

2.50 out of 5 stars

Medical Sector

108th out of 1,353 stocks

Pharmaceutical Preparations Industry

50th out of 666 stocks

Analyst Opinion: 3.6Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -












Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions

Is Ocular Therapeutix a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ocular Therapeutix stock.
View analyst ratings for Ocular Therapeutix
or view top-rated stocks.

What stocks does MarketBeat like better than Ocular Therapeutix?

Wall Street analysts have given Ocular Therapeutix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ocular Therapeutix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Ocular Therapeutix's next earnings date?

Ocular Therapeutix is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Ocular Therapeutix
.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) posted its earnings results on Monday, August, 9th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.20) by $0.09. Ocular Therapeutix had a negative net margin of 318.77% and a negative trailing twelve-month return on equity of 51.58%.
View Ocular Therapeutix's earnings history
.

How has Ocular Therapeutix's stock been impacted by Coronavirus (COVID-19)?

Ocular Therapeutix's stock was trading at $5.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OCUL stock has increased by 97.9% and is now trading at $10.59.
View which stocks have been most impacted by COVID-19
.

What guidance has Ocular Therapeutix issued on next quarter's earnings?

Ocular Therapeutix updated its second quarter 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $11.70 million-$11.70 million, compared to the consensus revenue estimate of $11.60 million.

What price target have analysts set for OCUL?

5 equities research analysts have issued 1 year price targets for Ocular Therapeutix's shares. Their forecasts range from $17.00 to $33.00. On average, they expect Ocular Therapeutix's stock price to reach $26.00 in the next twelve months. This suggests a possible upside of 145.5% from the stock's current price.
View analysts' price targets for Ocular Therapeutix
or view top-rated stocks among Wall Street analysts.

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the following people:
  • Antony Mattessich, President, Chief Executive Officer & Director
  • Donald Notman, Chief Financial & Accounting Officer
  • Peter Jarrett, Chief Scientific Officer
  • Michael H. Goldstein, Chief Medical Officer & Ophthalmology President
  • Rabia Gurses Ozden, Senior Vice President-Clinical Development

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), (CELG), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.53%), Vanguard Group Inc. (4.79%), State Street Corp (2.27%), Emerald Mutual Fund Advisers Trust (1.73%), Geode Capital Management LLC (1.70%) and Emerald Advisers LLC (1.60%). Company insiders that own Ocular Therapeutix stock include Antony C Mattessich, Opaleye Management Inc, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends for Ocular Therapeutix
.

Which institutional investors are selling Ocular Therapeutix stock?

OCUL stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., BlackRock Inc., Millennium Management LLC, Goldman Sachs Group Inc., Great Point Partners LLC, Emerald Advisers LLC, Altium Capital Management LP, and Ensign Peak Advisors Inc.
View insider buying and selling activity for Ocular Therapeutix
or view top insider-selling stocks.

Which institutional investors are buying Ocular Therapeutix stock?

OCUL stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Kornitzer Capital Management Inc. KS, Renaissance Technologies LLC, State Street Corp, Kamunting Street Capital Management L.P., First Trust Advisors LP, Morgan Stanley, and Morgan Stanley. Company insiders that have bought Ocular Therapeutix stock in the last two years include Antony C Mattessich, Opaleye Management Inc, and Summer Road Llc.
View insider buying and selling activity for Ocular Therapeutix
or or view top insider-buying stocks.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $10.59.

How much money does Ocular Therapeutix make?

Ocular Therapeutix has a market capitalization of $811.01 million and generates $17.40 million in revenue each year. The biopharmaceutical company earns $-155,640,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis.

How many employees does Ocular Therapeutix have?

Ocular Therapeutix employs 181 workers across the globe.

What is Ocular Therapeutix's official website?

The official website for Ocular Therapeutix is www.ocutx.com.

Where are Ocular Therapeutix's headquarters?

Ocular Therapeutix is headquartered at 15 CROSBY DRIVE, BEDFORD MA, 01730.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at (781) 357-4000 or via email at [email protected].


This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.